公开(公告)号：US20240327402A1

公开(公告)日：2024-10-03

申请号：US18576252

申请日：2022-08-03

Applicant: ABBISKO THERAPEUTICS CO., LTD.

Inventor： Tao FENG ,  Baowei ZHAO ,  Mingming ZHANG ,  Shuqun YANG ,  Hongping YU ,  Zhui CHEN ,  Yaochang XU

IPC: C07D471/04 ,  A61K31/506 ,  A61P35/00 ,  C07D403/04 ,  C07D403/14 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/506 ,  A61P35/00 ,  C07D403/04 ,  C07D403/14 ,  C07D519/00

Abstract: A pyrimidine or pyridine derivative having a structure represented by formula (I), a preparation method therefor, a pharmaceutical composition containing same, a use thereof as an EGFR inhibitor, and a use thereof in the preparation of a drug for treating and/or preventing cancer, tumors, or metastatic diseases associated at least in part with EGFR exon 20 insertions, deletions, or other mutations, especially a use thereof in the preparation of a drug for treating and/or preventing hyperproliferative diseases and the induction of cell death disorders.

公开(公告)号：US20240360102A1

公开(公告)日：2024-10-31

申请号：US18571418

申请日：2022-07-28

Applicant: Abbisko Therapeutics Co., Ltd.

Inventor： Fei YANG ,  Shuqun YANG ,  Hongping YU ,  Zhui CHEN ,  Yaochang XU

IPC: C07D401/14 ,  A61K31/506 ,  A61K31/5377

CPC classification number: C07D401/14 ,  A61K31/506 ,  A61K31/5377

Abstract: The present invention relates to a pyrimidine-4,6-diamine derivative, a preparation method therefor, and a pharmaceutical application thereof. Particularly, the present invention relates to a pyrimidine-4,6-diamine derivative having the structure of formula (I), a preparation method therefor, a pharmaceutical composition containing same, and a use of same as an EGFR inhibitor and a use of same in the preparation of drugs for the treatment and/or prevention of cancers, tumors, or metastatic diseases at least partially related to EGFR Del19 mutation, EGFR L858R mutation, EGFR L858R/C797S double mutation or EGFRDel19/C797S double mutation, in particular a use of same in the preparation of drugs for the treatment and/or prevention of hyperproliferative diseases and induced cell death disorders. The definition of each substituent in formula (I) is the same as that in the description.

公开(公告)号：US20200071302A1

公开(公告)日：2020-03-05

申请号：US16610970

申请日：2018-05-22

Applicant: Abbisko Therapeutics Co., Ltd.

Inventor： Baowei ZHAO ,  Mingming ZHANG ,  Hongping YU ,  Shuqun YANG ,  Zhui CHEN ,  Yaochang XU

IPC: C07D401/14 ,  C07D413/14 ,  A61P35/00

Abstract: An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.